CTRI/2021/06/034009尚未招募2/3 期
A RANDOMISED CONTROLLED CLINICAL TRIAL ON THE EFFICACY OF NIMBADI GUGGULU IN THE MANAGEMENT OF ARDHAVABHEDAKA(MIGRAINE)
DR AMRITHA MOHAN1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2021年6月20日最近更新:
试验速览
- 阶段
- 2/3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Bheda Todavat Shula( Intensity of pain)
研究概览
简要总结
This is a randomised open label single centre trial comparing the efficacy of Nimbadi guggulu and Padhyadi ghanavati for 30 days in 40 patients with migraineheadache will be conducted in Alvas ayurveda medical college Vidyagiri Moodbidri Dakshina kannada INdia. Primaryoutcome measures will be relief from Bheda Todavat Shula( Intensity of pain), Duration of single episode, Frequency of attack,Photophobia, nausea, vomiting in 90 days·
·
·
·
研究设计
- 研究类型
- Interventional
- 分配方式
- Coin toss, Lottery, toss of dice, shuffling cards etc
- 盲法
- Open Label
入排标准
- 年龄范围
- 16.00 Year(s) 至 60.00 Year(s)（—）
- 性别
- All
入选标准
- •Patients aged 16 – 60 years irrespective of gender religion and socioeconomic status will be selected Patients presenting with clinical features of Ardhavabhedaka will be selected.
排除标准
- •Patients having other types of Shirashula apart from Ardhavabhedaka will be excluded.
- •Patients suffering from secondary headaches like sinusitis, meningitis etc.
- •will be excluded.
- •Patients with any other systemic diseases and pregnancy will be excluded.
结局指标
主要结局
Bheda Todavat Shula( Intensity of pain)
时间窗: 90 DAYS
Duration of single episode
时间窗: 90 DAYS
Frequency of attack
时间窗: 90 DAYS
Photophobia
时间窗: 90 DAYS
Nausea
时间窗: 90 DAYS
Vomiting
时间窗: 90 DAYS
次要结局
- NOT APLICABLE(NOT APLICABLE)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast CancerBreast Cancer FemaleNCT02980965Fudan University249
招募中
不适用
Umbilical Cord Blood NK Cell Therapy for High-Risk Pediatric Soft Tissue Sarcoma: Efficacy and Safety StudyNCT06848582Sun Yat-sen University40
招募中
1 期
Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALLB-cell Acute Lymphoblastic LeukemiaB-ALLNCT05639179920th Hospital of Joint Logistics Support Force of People's Liberation Army of China30
撤回
1 期
Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALLB-cell Acute Lymphoblastic LeukemiaB-ALLNCT05571540Kunming Hope of Health Hospital
已完成
4 期
LIthium as Bridging thErapy Prior to Radioactiveiodine in hyperThYroidismHyperthyroidism/ThyrotoxicosisNCT05512715Universiti Kebangsaan Malaysia Medical Centre90